Phase II, Pilot Study, Open Label, Multicenter, Evaluating Dual Antiretroviral Therapy with Long-acting Cabotegravir/lenacapavir
Latest Information Update: 30 Oct 2024
Price :
$35 *
At a glance
- Drugs Cabotegravir (Primary) ; Cabotegravir (Primary) ; Lenacapavir (Primary)
- Indications HIV-1 infections
- Focus Therapeutic Use
- Acronyms CALENDULA
- 30 Oct 2024 New trial record